Creative Biolabs Accelerates Complement-Targeted Drug Discovery with Advanced Solutions

SHIRLEY, NY – March 24, 2026 – The complement system is now a primary target in drug development, central to immunology. This intricate protein network offers immense potential for treating diverse conditions, from rare disorders to neurodegenerative diseases. Creative Biolabs, an immunology-based drug discovery specialist, introduces comprehensive solutions addressing critical bottlenecks in complement therapeutic development, emphasizing high-resolution functional analysis.

Creative Biolabs' core offering is the refined individual complement component activity assay. This specialized testing precisely measures the functional integrity of specific proteins (e.g., C1q, C3), enabling developers to pinpoint exact therapeutic intervention sites while preserving non-targeted immune functions. These methodologies enhance data reproducibility, crucial for clinical trials, and are optimized for seamless integration with automated laboratory platforms, supporting high-throughput research.

Further bolstering discovery, Creative Biolabs provides customization and fabrication for advanced microfluidic systems. These custom-engineered chips create biomimetic environments, offering predictive insights into how therapies perform in the human body, significantly reducing risks for in vivo studies. Creative Biolabs thus empowers the global pharmaceutical industry, accelerating the discovery and development of effective complement-targeted treatments. Learn more at creative-biolabs.com/complement-therapeutics.